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Introduction 
Advances in genetics research are extremely important in the treatment and diagnosis of 
disease.
1
  Technological innovations provide researchers with the means to sequence entire 
genomes and publicly disseminate the data through private and public genetic databases.
2
  
However, genetic research has raised some ethical and legal concerns.
3
  Specifically, the increase 
in access to genetic information has threatened the genetic privacy of individuals who either 
directly or indirectly participate in genetics research.
4
   
Genetic information is considered highly sensitive and private for several reasons.
5
  Access 
to an individual’s genetic information will disclose that person’s traits, disease patterns, and 
family history.
6
  Consequently, if this information is disclosed to the wrong person, that person 
could gain access into an individual’s future, past, and present.7  Critics of the availability of 
genetic information believe that it will be used unfairly in employment practices.
8
  A 
discouraging genetic makeup could reduce employment prospects or even cause an employer to 
deny an employee insurance coverage based on genetic information received.
9
  The availability 
of genetic research may also be used by insurance providers in making coverage decisions.
10
  
In response to the aforementioned privacy concerns of genetic research, federal legislation 
has been developed and amended.
11
  Congress recently enacted the Genetic Information and 
                                                            
1 Kristie Sosnowski, Genetic Research: Are More Limitations Needed in the Field, 15 J.L. & HEALTH 121, 136 (2001). 
2 Sarah Fendrick, The Role of Privacy Law in Genetic Research, 4 J.L. & POL’Y FOR INFO. SOC’Y 803, 804 (2008).   
3 Sosnowski, supra note 1, at 136. 
4 Fendrick, supra note 2, at 804. 
5 Sosnowski, supra note 1, at 136. 
6 Id. at 137. 
7 Id.  
8 Id. 
9 Id. 
10Id. 
11 Id. at 139. 
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Nondiscrimination Act of 2008 (hereinafter “GINA”) to restrict the use of genetic information by 
insurance and health care providers and in employment practices.
12
  Also, the Health Insurance 
Portability and Accountability Act of 1996 (hereinafter “HIPAA”), was enacted to ensure the fair 
use of genetic information by insurance providers
13
 and to preserve the confidentiality of an 
individual’s protected health information.14  However, the incomprehensive nature of the federal 
legislation has prompted states to enact laws that address the privacy concerns of genetic 
research.
15
  
This article first provides a basic understanding of genetic testing and research of human 
tissue samples.  Next, this article will provide an overview of the major federal legislation, GINA 
and HIPAA, which have been passed in an effort to remedy the privacy concerns of genetics 
research.  Furthermore, the article will discuss whether the states have adequately supplemented 
the federal legislation.  This article will primarily focus on New Jersey and New York law as it 
will be argued that other states should adopt a similar statutory framework in order to establish 
more uniform and stringent laws on the use and disclosure of genetics research.  Finally, this 
article will propose solutions to effectively address the individual privacy concerns of genetics 
research while still allowing for the scientific advancement of genetics research in order to 
benefit humanity. 
I. Genetic Tests and their Administration 
A genetic test has generally been as defined as the analysis performed on human 
deoxyribonucleic acid (hereinafter “DNA”),  ribonucleic acid (hereinafter “RNA”), genes and/or 
                                                            
12 Id. 
13 Id. at 140. 
14 Elizabeth Hutton & Devin Barry, Privacy in Review: Developments in HIPAA, 1 J.L. & POL’Y FOR INFO. SOC’Y 347, 347 
(2004).   
15 Fendrick, supra note 2, at 804. 
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chromosomes in order to detect heritable and acquired genotypes, mutations, phenotypes, or 
karyotypes that cause or are likely to cause a specific disease or condition.
16
  A genetic test also 
is the analysis of human proteins and certain metabolites, which are predominantly used to detect 
heritable or acquired genotypes, mutations, or phenotypes.
17
   
Specifically, there are two general types of health-related genetic tests: diagnostic and 
predictive.
18
  Diagnostic tests are used to identify the presence or absence of a disease.
19
  In 
contrast, predictive genetic tests are used to predict whether an individual will develop a genetic 
disorder in the future before any signs or symptoms are manifested.
20
  Early diagnosis and 
treatment of severe genetic diseases lead many to believe that the benefits of genetics testing and 
research outweigh the risks,
21
 such as discrimination by employers and/or health insurance 
providers if an individual’s genetic information is distributed without their knowledge.22   
For example, if a tissue provider learns through genetics research that she carries the gene for 
Huntington’s disease, then breaches of confidentiality may be detrimental to the interests of that 
tissue provider.
23
  If third parties, such as an insurance provider or employers gain access to this 
information, they may find ways to refuse, limit, or terminate that individual’s insurance, 
employment, or other opportunities.
24
  Also, genetic material identifies not only the individuals 
                                                            
16 Laren E. Nuffort, The Genetic Information Nondiscrimination Act of 2008: Raising a Shield to Genetic 
Discrimination in Employment and Health Insurance, 21 no. 5 HEALTH LAW 1, 5 (2009).   
17 Id. 
18 Id. 
19 Id. 
20 Id. 
21 Sosnowski, supra note 1, at 133. 
22 Id. at 137. 
23 Natalie Ram, Assigning Rights and Protecting Interests: Constructing Ethical and Efficient Legal Rights in Human 
Tissue Research, 23 HARV. J.L. & TECH. 119, 130 (2009). 
24 Id. 
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who provide it, but close family members as well.
25
  Thus, not only do consenting tissue 
providers have a stake in the confidentiality of their genetic information, but so do their genetic 
relatives.
26
  Consequently, genetic information that is disclosed to an unauthorized source, such 
as insurance providers or employers, raise substantial privacy concerns.
27
  
Traditionally, researchers have taken a number of steps to protect the confidentiality of tissue 
providers.
28
  Specifically, tissue samples may be coded, meaning that they are assigned a number 
that corresponds to a secret file containing identifying information.
29
  Thus, identifying 
information for a particular tissue sample can only be obtained with access to a decoding 
program or database.
30
   
Moreover, researchers and institutions may “anonymize” tissue samples, a process designed 
to completely and permanently separate the sample from identifying information.
31
  However, 
with emerging technology, it is unclear whether true anonymization can ever be achieved.
32
  
DNA is as individually identifying as a fingerprint, and thus any individual cell could be traced 
back to its source.
33
   
On the other hand, society has a profound interest in promoting genetics research using 
human tissue in order to advance scientific development.
34
  In particular, societal interests may 
include facilitating researcher access to research materials, incentivizing investment in high 
                                                            
25 Id. at 132.  
26 Id.  
27 Sosnowski, supra note 1, at 133.  
28 Ram, supra note 23, at 131. 
29 Id. 
30 Id. 
31 Id. 
32 Id. at 132. 
33 Id. 
34 Id. at 137. 
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quality research, and ensuring that research is conducted in a responsible and ethical matter.
35
  
Simple and inexpensive access to the raw materials of research is critical to promoting 
investment in science and medicine.
36
  However, if the interests of research participants are 
inadequately protected, then potential tissue providers will simply refuse to participate in 
genetics research.
37
  Therefore, the scientific advancement of genetics research should be 
balanced with the protection of individual privacy interests.
38
   
II. Overview of Federal Legislation 
A. Health Insurance Portability and Accountability Act of 1996 
     The HIPAA Privacy Rule is the first federal law to protect health information created or 
received by health care providers and health plans.
39
  Specifically, as applied only to “covered 
entities,” HIPAA limits the circumstances under which “protected health information” may be 
disclosed.
40
  If an entity is a “covered entity,” it may not disclose “protected health information” 
except as required or permitted by HIPAA.
41
  The Privacy Rule of HIPAA requires covered 
entities to adhere to a “minimum necessary” standard when disclosing protected health 
information.
42
  The “minimum necessary” standard provides that when disclosing protected 
health information, a covered entity must make “reasonable efforts to limit protected health 
                                                            
35 Id.  
36 Id. 
37 Id. at 176. 
38 Id. at 138. 
39 Joanne L. Hustead & Janlori Goldman, Genetics and Privacy, 28 AM. J.L. & MED. 285, 289 (2002).   
40 Jonathan Hsu, Genetic Testing: Balancing Preventive Medicine with Privacy and Nondiscrimination, 6 J.L. & POL’Y 
FOR INFO. SOC’Y 557, 577 (2011).   
41 45 C.F.R. § 164.502 (2013). 
42 Id. at § 164.502(b). 
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information to the minimum necessary to accomplish the intended purpose of the use, disclosure, 
or request.”43     
     A “covered entity” is defined as “a health plan,” “a health care clearinghouse,” “a health care 
provider who transmits any health information in electronic form in connection with a 
transaction covered by this subchapter,”44 or a “business associate” of another covered entity.45  
A “health plan” is any plan that pays for health care serves such as Medicare, Medicaid, any state 
or federal health plan, private health plans, and employer self-funded health plans.
46
  Health 
maintenance organizations also fall within the contours of a “health plan.”47  Additionally, a 
“health care clearinghouse” is any entity that compiles health care information,48 such as 
computer data processing centers and billing companies, which aggregate and process 
computerized health information.
49
  Moreover, a “health care provider” is anyone who furnishes, 
bills, or is paid for healthcare in the normal course of business, such as doctors, nurses, 
therapists, hospitals, medical technicians, nursing homes, rehabilitation centers, psychologists, 
pharmacists, and therapists.
50
  Finally, “business associates” of a covered entity are those 
individuals and entities, such as lawyers, accountants, or certain vendors, that are required to 
have access to and knowledge of “protected health information,” must also abide by HIPAA’s 
requirements.
51
 
                                                            
43 Id. at § 164.502(b)(1). 
44 Id. at § 160.102; 42 U.S.C. § 1320d-1 (1996). 
45 45 C.F.R. at § 160.103.   
46 Id. 
47 Id. 
48 Id. 
49 Id.; 42 U.S.C. at § 1320d(3). 
50 45 C.F.R. at § 160.103.    
51 Id. 
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     Furthermore, “protected health information” (hereinafter “PHI”) is broadly defined under 
HIPAA as “individually identifiable health information,”52 which does not explicitly include 
genetic information.
53
  However, the U.S. Department of Health and Human Services 
(hereinafter “HHS”) has clarified that “genetic information” is covered as “PHI” under the 
Privacy Rule.
54
  Every covered entity is obligated to protect the confidentiality of individually 
identifiable information.
55
  Permitted disclosures of PHI are those disclosures to the individual or 
those disclosures for the purpose of “treatment, payment, or health care operations.”56  A covered 
entity may also disclose PHI to the extent as required by law.
57
  Only covered entities are 
required to comply with the HIPAA privacy regulations, whereas non-covered entities, such as 
research laboratories, are not required to comply.
58
  Therefore, genetic information used in 
research is afforded the same protection under HIPAA as other health care information only if 
the researcher is characterized as a “covered entity.”59     
     In 2013, HHS released final regulations expanding privacy rights for patients and others 
under the Privacy Rule of HIPAA.
60
  The regulations expand many of the requirements to 
business associates of entities that receive protected health information, such as contractors and 
subcontractors.
61
  Ostensibly, some of the largest breaches reported to the HHS have involved 
                                                            
52 Id. (“Protected health information means individually identifiable health information that is: (i) transmitted by 
electronic media; maintained in electronic media; or transmitted or maintained in any other form or medium.” Id.) 
53 Id.    
54 U.S. Department of Health & Human Services, Health Information Privacy, March 14, 2006, available at 
http://www.hhs.gov/ocr/privacy/hipaa/faq/protected_health_information/354.html (last visited at April 5, 2013). 
55 45 C.F.R. at § 164.502(a). 
56 Id. 
57 Id. at § 164.512(a)(1). 
58 Fendrick, supra note 2, at 808.   
59 Id. at 809.   
60 U.S. Department of Health & Human Services, News Release, Jan. 17, 2013, available at 
http://www.hhs.gov/news/press/2013pres/01/20130117b.html (last visited at April 5, 2013).   
61 Id. 
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business associates.
62
  Consequently, penalties are increased for noncompliance based on the 
level of negligence with a maximum penalty of $1.5 million per violation.
63
  Also, individual 
rights are expanded in important ways.
64
  Patients can ask for a copy of their electronic medical 
record in an electronic form.
65
  When individuals pay by cash they can instruct their provider not 
to share information about their treatment with their health plan.
66
  There are also limits on how 
information is used and disclosed for marketing and fundraising purposes and prohibits the sale 
of an individuals’ health information without their permission.67   
     Moreover, HIPAA addresses the concerns associated with the use of genetic information by 
insurance providers.
68
  HIPAA provides that “genetic information shall not be treated as a [pre-
existing] condition in the absence of a diagnosis of the condition related to such information.”69  
Also, HIPAA precludes insurance providers offering a group health insurance plan from 
requiring an individual to pay a higher premium than those similarly situated, based solely on the 
individual’s health information, which includes genetic information.70  In essence, HIPAA 
prohibits insurers from using genetic information to deny or limit health insurance coverage.
71
 
     On the other hand, there are many ways that insurers can obtain and adversely use genetic 
information that are not precluded by HIPAA.
72
  For example, insurers in the group market may 
charge an entire group of any size more than another group because of the genetic information of 
                                                            
62 Id. 
63 Id. 
64 Id. 
65 Id.  
66 Id. 
67 Id. 
68 Sosnowski, supra note 1, at 144; 29 U.S.C. § 1182(a)(1)(F) (2008).   
69 29 U.S.C. § 1181(b)(1)(B).   
70 Id. at § 1881(b)(3)(A).   
71 Sosnowski, supra note 1, at 145. 
72 Hustead, supra note 39, at 292. 
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one individual in the group.
73
  Also, insurers may request, require, purchase or otherwise collect 
an applicant’s genetic information in the group and individual markets.74  Furthermore, insurers 
in the group market may refuse to cover an entire group because of the genetic information of 
one individual in the group.
75
  
     Additionally, employers may learn about the health status and medical conditions of their 
employees and dependents, in various ways.
76
  One important source of this information is 
medical examinations required by employers.
77
  Research demonstrates that employers use 
results from medical examinations when making decisions about hiring, placement, retention, 
and dismissal.
78
  Another important avenue for collection of medical information is through 
health claims submitted to employer-sponsored health plans.
79
  All of the ways in which 
employers may obtain health information could result in employers obtaining genetic 
information.
80
  An employer that provides health care services to its employees may be a “health 
care provider” that is required to comply with the HIPAA regulations.81  Under HIPAA, only 
employees involved in plan administration would have access to PHI.
82
  Although its protections 
are substantial, HIPAA does not prevent genetic discrimination by employers.
83
   
                                                            
73 Id.  
74 Id. 
75 Id. 
76 Id. at 293. 
77 Id. 
78 Id. 
79 Id.  
80 Id.  
81 Id. at 291. 
82 45 C.F.R. § 164.504(f)(2)(iii). 
83 Hutton, supra note 14, at 368.   
11 
 
     Therefore, a substantial inadequacy of the HIPAA regulations is its failure to reach all people 
or entities that have access to PHI,
84
 such as tissue banks or researchers.
85
  Also, while HIPAA 
addresses certain genetic discrimination practices, it was not created for the sole purpose of 
preventing genetic discrimination.
86
  Because HIPAA sets a federal floor of privacy 
protections,
87
 state laws that are less protective of privacy are preempted.
88
   
B. Genetic Information and Nondiscrimination Act of 2008 
GINA amended a variety of federal statutes, including HIPAA, in order to limit health 
insurers’ use of genetic information in making decisions about plan enrollment and in adjusting 
premiums.
89
   It also regulates how employers may use and store genetic information.
90
  Pursuant 
to GINA, “genetic information” is defined as the following: “(i) the individual’s genetic tests;  
(ii) the genetic tests of family members of such individual; and (iii) the manifestation of a disease 
or disorder in family members of such individual,”91 which does not include sex or age.92   
A “genetic test” pursuant to GINA is defined as “an analysis of human DNA, RNA, 
chromosomes, proteins, or metabolites, that detects genotypes, mutations, or chromosomal 
changes.”93  But there are exceptions that provide that a genetic test is not “an analysis of 
proteins or metabolites that does not detect genotypes, mutations, or chromosomal changes,”94 or 
“an analysis of proteins or metabolites that is directly related to a manifested disease, disorder, or 
                                                            
84 Id.   
85 Christina Strong et. al., Healthcare Privacy laws- Covered Entities, 2012 § 10:6 (2012).  
86 Hutton, supra note 14, at 376. 
87 Hustead, supra note 39, at 292. 
88 Id. at 293. 
89 29 U.S.C. § 1182(b)(1).   
90 42 U.S.C. § 2000ff-1(a) (2008).  
91 Id. at § 2000ff(4).   
92 Id. at § 2000ff(4)(C).   
93 Id. at § 2000ff(7). 
94 Id. at § 2000ff(7)(B); Id. at § 300gg-91(17(B)(i).  
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pathological condition.”95  These definitions under GINA do not provide much guidance as to 
the types of tests considered genetic.
96
 
Specifically, Title I of GINA amended HIPAA in order to prevent group health plans and 
group health insurance issuers from setting group premium or contribution amounts on the basis 
of genetic information.
97
  Additionally, GINA prohibits plans and issuers from requesting or 
requiring an individual to undergo genetic tests, and prohibits a plan from collecting genetic 
information (including family history) prior to or in connection with enrollment,
98
 or for 
underwriting purposes.
99
  Under GINA, underwriting purposes include rules for determination of 
eligibility for benefits and the computation of premium and contribution amounts.
100
  In other 
words, plans or issuers are generally prohibited from offering rewards in return for completing a 
health risk assessment that requests genetic information, including family medical history.
101
  An 
exception will allow genetic testing to be requested, but not required, for research purposes when 
certain conditions are satisfied.
102
     
On the other hand, there are some examples where a health insurance plan may obtain or use 
genetic information that are permitted under GINA.
103
  First, a health insurance plan may 
recommend to an individual that he or she may want to undergo a genetic test for purposes of 
disease management or prevention.
104
  However, the health insurance plan may only recommend 
                                                            
95 Id. at §  300gg-91(17(B)(ii).   
96 Mark A. Rothstein, GINA, the ADA, and Genetic Discrimination in Employment, 36 J.L. MED & ETHICS 837, 838 
(2008).   
97 26 U.S.C. § 9802(b)(3) (2008).   
98 Id. at § 9802(d)(2).   
99 Id. at § 9802(d)(1).   
100 Id. at § 9832(d)(10). 
101 Eric N. Miller, The Genetic Information Nondiscrimination Act of 2008, 2015, 2016 (2013).    
102 26 U.S.C. § 9802(c)(4).   
103 Nuffort, supra note 16, at 15.   
104 Id. 
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the genetic test to the individual; it cannot request or require that the test be taken.
105
  Also, when 
certain conditions are satisfied, health insurance plans may request that an individual undergo a 
genetic test for research purposes.
106
    
Moreover, Title II of GINA amended HIPAA in order to prohibit private employers, state 
and federal governmental entities, labor organizations, employment agencies, and joint labor-
management committees from discriminating against an employee based on genetic 
information.
107
  An employer engages in an unlawful employment practice if the employer 
requests, requires, or purchases the genetic information of an employee or family member of that 
employee.
108
   
However, there are certain exceptions to this prohibition.
109
  First, an employer who 
inadvertently requests or requires an employee’s medical history or an employee’s family 
members’ medical history has not committed a violation.110  Second, an employer can offer 
health or genetic services whereby an employee gives prior, knowing, voluntary, and written 
authorization, and only the employee or employee’s family member and a licensed health care 
professional receive the results.
111
  This information may be available only for purposes of such 
services and cannot be disclosed to the employer except in aggregate terms that do not disclose 
the employee’s identity.112  Third, an employer may request or require family medical history 
                                                            
105 Id. 
106 Id. 
107 42 U.S.C. § 2000ff-1(2).   
108 Id. at § 2000ff-1(b).   
109 Id. 
110 Id. at § 2000ff-1(b)(1). 
111 Id. at § 2000ff-1(b)(2)(B). 
112 Id. at § 2000ff-1(b)(2)(C). 
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from the employee in order to comply with state family or medical leave laws.
113
  Finally, an 
employer is permitted to purchase publicly available documents of family medical history.
114
   
Accordingly, GINA provides that unlawful employment practices include failing to hire, 
discharging, or otherwise affecting a term, condition, or privilege of employment resulting from 
genetic information received.
115
  It also prevents an employer from limiting, segregating, or 
classifying employees, or tending to deprive them of employment opportunities on the basis of 
genetic information.
116
  Also, in the event that an employer does obtain access to an individual’s 
genetic information, such information must be kept on separate forms and in separate medical 
files.
117
  The information must be treated as confidential medical records of the employee.
118
 
A major concern for both employers and insurers is GINA’s overly broad definition of 
“genetic test.” 119  The health care industry has recommended that the definition of “genetic test” 
be limited to predictive testing performed on asymptomatic or undiagnosed individuals for the 
purpose of assessing the risk of future diseases; because the industry was concerned that the 
broad definition of “genetic test” would force employers to offer health plan coverage for all 
treatments for genetically related conditions.
120
  Also, the broad definition of “genetic test” may 
increase the number of GINA-based lawsuits.
121
  However, Congress did not adopt the health 
industry’s recommendation.122 
                                                            
113 Id. at § 2000ff-1(b)(3). 
114 Id. at § 2000ff-1(b)(4). 
115 42 U.S.C. § 2000ff-1(a)(1).   
116 Id. at § 2000ff-1(a)(2).   
117 Id. at § 2000ff-5(a).   
118 Id. 
119 Stephen E. Trimboli & Marissa B. Ruggiero, Navigating the Genetic Information Nondiscrimination Act of 2008, 
24, 27 (2011). 
120 Id. at 27.  
121 Id.  
122 Id. at 28. 
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For example, in a recent case, the U.S. District Court for the Western District of North 
Carolina held that the plaintiff failed to state a cognizable claim pursuant to Title II of GINA.
123
  
The plaintiff alleged that he was rejected from employment because of his failure to pass initial 
screening tests.
124
  However, the court held that there were no allegations that the employer 
asked for or obtained the plaintiff’s genetic information.125  Also, the court held that even if the 
employer did obtain the plaintiff’s genetic information, the facts did not suggest that such 
information was used to discriminate against the plaintiff.
126
   
Furthermore, the U.S. District Court for the Southern District of Florida dismissed plaintiff’s 
complaint without prejudice because it failed to allege that the defendant required him to take a 
genetic test, that the defendant had otherwise obtained the plaintiff’s genetic information, or that 
the defendant had discovered specific genetic information that caused it to deny employment to 
the plaintiff.
127
  There was also an issue as to the timing of the alleged discrimination.
128
  Any 
alleged violations taking place prior to Nov. 21, 2009, predate the effective date of Title II of 
GINA, and thus are not actionable.
129
    
One of the purposes of GINA was to reconcile the various state laws that had been adopted 
on the issue of genetic discrimination and establish a “national and uniform basic standard.”130  
However, if that was truly Congress’ intent, one would expect Congress to preempt the 
legislation in this area.
131
  Instead, Title II of GINA expressly provides that its provisions cannot 
                                                            
123 Bullock v. Spherion, No. 3:10-cv-465, 2011 WL 1869933, at *4 (W.D.N.C., May 16, 2011). 
124 Id. at *1.  
125 Id. at *6. 
126 Id.  
127 Citron v. Niche Media/Ocean Drive Magazine, No. 10-24014- CIV, 2011 WL 381939, at *2 (S.D. Fla. Feb. 2, 2011). 
128 Id. 
129 Id. 
130 Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881, § 2(5) (2008). 
131 Trimboli, supra note 119, at 28.   
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be construed to “limit the rights or protections of individuals under any other Federal or State 
statute that provides equal or greater protection.”132  This provision seems inconsistent with the 
stated intention of creating a uniform national standard.
133
  Because of varying state laws and the 
rapid development of genetic science, there may be unintended consequences that arise from 
Congress’ inability to accurately predict future results subsequent to GINA’s adoption134   
C. Synthesis  
     A substantial inadequacy of HIPAA is its inability to reach all entities or persons that have 
access to an individual’s PHI.  HIPAA applies only to “covered entities” that have access to an 
individual’s PHI, which include “genetic information.”  Thus, entities such as certain research 
laboratories and tissue banks do not have to comply with HIPAA’s regulations and may freely 
disclose an individual’s identifiable genetic information to an unauthorized source, such as 
employers and/or health care providers.  Also, while HIPAA creates some restrictions on the use 
of an individual’s PHI, it was not created for the sole purpose of preventing discrimination by 
employers and/or health care providers.   
On the other hand, GINA amended HIPAA in order to preclude discriminatory conduct by 
employers and/or health insurance providers if they gain access to individual’s PHI.  However, 
while GINA improved the anti-discriminatory provisions of HIPAA, it does not prevent certain 
entities, such as research laboratories or tissue banks, from disclosing an individual’s identifiable 
genetic information to third parties without authorization.   
                                                            
132 42 U.S.C. § 2000ff-8(1).  
133 Trimboli, supra note 119, at 28. 
134 Id. at 27.   
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Therefore, federal legislation allows certain researchers and tissue banks to freely disclose to 
a third party an individual’s PHI, including identifiable genetic information, without 
authorization.  Consequently, employers and/or health care providers are still able to gain access 
to an individual’s PHI through researchers or tissue banks and possibly make discriminatory 
judgments based on this information.  Because of the incomprehensive nature of federal 
legislation, the states have implemented laws to effectively address these privacy concerns of 
genetics research.        
III. Overview of State Legislation 
A. “Genetic Information” and “Genetic Test”  
Inadequate federal legislation with regard to an individual’s genetic information has 
prompted states to pass laws that impose higher standards.
135
  State protections of genetic 
information do not mirror one another, and thus vary widely in their capabilities.
136
  Many states 
have passed legislation that place restrictions on what constitutes a genetic test and place limits 
on the collection and disclosure of genetic information.
137
  These restrictions have varying 
effects on genetic research, which depend on the definitions of “genetic information” and 
“genetic tests” and how broadly these terms are defined in the legislation.138  Consequently, the 
variety of definitions generates difficulty in determining the information that should be 
protected.
139
   
                                                            
135 Fendrick, supra note 2, at 812. 
136 Nuffort, supra note 16, at 9. 
137 Fendrick, supra note 2, at 812. 
138 Id.   
139 Michael S. Yesley, Protecting Genetic Difference, 13 BERKELEY TECH. L.J. 653, 661 (1998).   
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Accordingly, state legislation that narrowly defines “genetic information” may be easier to 
implement, but may not provide sufficient protection.
140
  For example, Massachusetts provides 
that genetic information “shall not include any information about an identifiable person that is 
taken: (1) as a biopsy, autopsy, or clinical specimen solely for the purpose of conducting an 
immediate clinical or diagnostic test that is not a test of DNA, RNA, mitochondrial DNA, 
chromosomes or proteins.”141  Therefore, Massachusetts distinguishes between research and 
clinical data.
142
   
In contrast, some states use broad definitions of “genetic test” that do not exclude certain 
research from their scope, which may restrict the ability of researchers to use tissue samples.
143
  
For example, “genetic test” is defined in Louisiana as “any test for determining the presence or 
absence of genetic characteristics in an individual, including tests of nucleic acids, such as DNA, 
RNA, and mitochondrial DNA, chromosomes, or proteins in order to diagnose or identify a 
genetic characteristic or that detects genotypes, mutation, or chromosomal changes.”144   
On the other hand, many statutes contain language similar to that found in Nebraska, which 
excludes from the definition of “genetic test” any activities undertaken as part of biomedical 
research: “Genetic test does not include a routine physical examination or a routine analysis, 
including a chemical analysis, of body fluids unless conducted specifically to determine the 
presence, absence, or mutation of a gene or chromosome.”145 
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B. Informed Consent  
Some states require informed consent from the individual providing the genetic material 
before the information and/or material can be disclosed for research purposes.
146
  Within a 
number of states requiring informed consent, specific provisions are included that regulate the 
retention and future use of blood and tissue samples.
147
  Specifically, Delaware, Nevada, New 
York, New Jersey, and Oregon have laws requiring researchers to obtain individual informed 
consent in order to retain “genetic information.”148   
For example, in New Jersey genetic privacy is regulated pursuant to New Jersey’s Genetic 
Privacy Act.
149
  The act prevents employers and insurance companies from discriminating 
against individuals on the basis of their genetic information.
150
  “Genetic information” is defined 
as the “information about genes, gene products or inherited characteristics that may derive from 
an individual or family member.”151  The act protects genetic privacy by mandating that genetic 
information be destroyed after completion of the research project unless individual consent is 
obtained to retain the sample.
152
 
Similarly, New York protects the confidentiality of records of genetic tests.
153
  New York 
law imposes stringent requirements for informed consent and retention of samples for limited 
periods, but the law permits the research on anonymous samples, pursuant to a research protocol 
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approved by an institutional review board (hereinafter “IRB”), when the identity of the 
individuals is protected.
154
  In general, New York prohibits the conduct of “genetic tests” without 
the prior written informed consent of the individual.
155
  A “genetic test” is defined as:  
…Any laboratory test of human DNA, chromosomes, genes, or gene products 
to diagnose the presence of a genetic variation linked to a predisposition to a 
genetic disease or disability in the individual or the individual’s offspring; such 
term shall also include DNA profile analysis.  ‘Genetic test’ shall not be deemed 
to include any test of blood or other medically prescribed test in routine use that 
has been or may be hereafter found to be associated with a genetic variation 
unless conducted purposely to identify such genetic variation.
156
  
According to the New York statute, valid informed consent must be obtained prior to a 
“genetic test.”157  Specific elements must be incorporated into the informed consent form, which 
include the following: a general description of each specific disease or condition that will be 
tested, the level of certainty that a positive test result for that disease or condition serves as a 
predictor of such disease, the name of the person or categories of persons or organizations to 
whom the test results may be disclosed, and a statement that no tests other than those authorized 
shall be performed on the biological sample.
158
 
For clinical genetic tests, the informed consent must provide that the sample shall be 
destroyed at the end of the testing process, or not more than sixty days after the sample was 
taken, unless a longer period of retention is expressly authorized in the consent.
159
  New York 
law requires individual authorization for sample retention for up to ten years if no genetic testing 
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is performed; however, informed consent must be obtained prior to the conduct of genetic 
tests.
160
 
On the other hand, for research (rather than for clinical purposes), New York law provides 
that samples may be used without individual informed consent when IRB approval of the 
research protocol is given, as long as the identity of the individual has been removed, the results 
are not linked to the person, and no information relating to the identity of the individual is 
disclosed.
161
  Therefore, for the purposes of compliance with the New York law, the samples and 
data may be used as proposed, as long as IRB approval is obtained, and the information 
regarding individual identities is protected.
162
 
Moreover, individual ownership of “genetic information” has been declared by four states: 
Colorado, Florida, Georgia, and Louisiana.
163
  However, of the four states that declare that 
genetic information is “owned” by the individual, three of them (Colorado, Georgia, and 
Louisiana) permit the use of “genetic information” for research purposes when the identity of the 
individual is not disclosed.
164
  Thus, while these provisions appear restrictive, they permit the use 
and retention of genetic information for research purposes when the data are anonymous.
165
 
Finally, Michigan and Nebraska also have identical statutes for the conduct of “genetic 
tests,” which impose a strict requirement to obtain informed consent from individuals that 
incorporates a statement of future uses of the sample and who will have access to the sample.
166
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Both states permit research without informed consent when research is conducted pursuant to 
federal regulations.
167
  Similarly, South Carolina imposes strict limits on the conduct of genetic 
tests for clinical purposes, but permits the use of samples and information for research purposes 
when patient identities are not disclosed.
168
    
C. Synthesis  
A noteworthy addition to the federal legislation has been the states’ broad definition of 
“genetic information” or “genetic test” in conjunction with a comprehensive informed consent 
procedure prior to any genetic testing/research.  A broad definition of “genetic information” or 
“genetic test” places most research within the scope of the statute.   
Furthermore, a comprehensive informed consent procedure restricts the use and disclosure of 
an individual’s identifiable genetic information.  Generally, the informed consent form requests 
information from the research participant regarding future use of the genetic sample, such as 
permissible disclosures to third parties.  Specifically, New York mandates that informed consent 
must be obtained prior to any “genetic test.”  Similarly, in New Jersey, all “genetic information” 
must be destroyed after genetics research and/or genetic testing, unless the individual participant 
provides otherwise.  This ensures that an individual’s identifiable genetic information is not 
being released to an unauthorized third party after the research and/or testing has been 
completed.   
Therefore, when the data of a genetic sample is not anonymous, certain states have 
adequately protected the unauthorized disclosure of an individual’s “genetic information” 
through an informed consent procedure prior to genetics research and/or testing.  A 
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comprehensive informed consent procedure ensures that an individual’s identifiable genetic 
information is not released to an unauthorized third party, thus preserving that individual’s 
genetic privacy.    
IV. Proposed Recommendations to Preclude Unauthorized Disclosure of an 
Individual’s Identifiable Genetic Information 
Although genetics research provides invaluable information in the study and treatment of 
diseases, there is a substantial privacy concern with respect to an individual’s identifiable genetic 
information following the completion of genetics research and/or testing.  There are certain 
research entities that are not regulated by federal or state law and pose a threat to an individual’s 
genetic privacy by freely disseminating an individual’s identifiable “genetic information” 
without authorization.   
Specifically, in order to address the ongoing privacy concerns of genetics research, the 
following recommendations are proposed: (1) HIPAA should be amended to mandate that any 
person or entity with access to an individual’s PHI must comply with HIPAA’s privacy 
regulations; (2) a majority of states should adopt a statutory framework similar to New Jersey 
and New York law, which include informed consent provisions, in order to preclude the 
unauthorized disclosure of an individual’s identifiable genetic information; or (3) Congress 
should preempt the entire field on this matter in order to establish more uniformity.  These 
changes will reach a balance that protects an individual’s genetic privacy while still allowing for 
the scientific advancement of genetics research to progress for the benefit of humanity.      
First, HIPAA could be amended to mandate that any person or entity with access to an 
individual’s PHI must comply with the HIPAA privacy regulations.  Most research laboratories 
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or tissue banks do not fall within the definition of a “covered entity.”  This amendment would 
regulate those certain research laboratories or tissue banks that do genetics research/testing or 
any other person that has access to an individual’s identifying “genetic information.”  Thus, if a 
research laboratory has done genetics research or testing, that research laboratory can only 
disclose that individual’s identifying “genetic information” to the individual research participant, 
or those necessary disclosures for the purpose of “treatment, payment, or health care operations.”  
This amendment to HIPAA would ensure that confidentiality of an individual’s identifying 
genetic information is preserved and only used or disclosed as needed.   
Next, the states could adopt a statutory framework similar to New Jersey and New York in 
order to preclude the unauthorized disclosure of an individual’s identifiable genetic information.  
New Jersey mandates that unless the research participant authorizes otherwise, an individual’s 
genetic information must be destroyed after the completion of genetic research or testing.  Also, 
New York mandates that informed consent must be obtained prior to any “genetic test.”  The 
informed consent requests information with regard to future use of the genetic sample, such as 
authorized disclosures.  Furthermore, New York suggests a longer retention of genetic 
information if anonymity is preserved along with IRB approval.  Therefore, so long as there is no 
identifying link between the sample and the research participant, then a longer retention of the 
sample could be permissible.  Adopting a similar statutory framework will ensure that an 
individual’s identifiable genetic information is not freely disseminated to unauthorized third 
parties, such as employers and/or health care providers.   
Finally, another option to precluding the unauthorized disclosure of an individual’s 
identifiable genetic information could be for Congress to preempt the entire area of law on this 
particular matter.  HIPAA could be amended as the first proposal suggests to mandate that any 
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person or entity with access to an individual’s PHI must comply with the HIPAA privacy 
regulations.  Moreover, HIPAA could also be amended to incorporate similar informed consent 
provisions as noted in the second proposal.  As a result, there would be more uniformity on the 
type of conduct that is regulated.  This would establish a more “national and uniform basic 
standard,” as originally intended by Congress, and ensure the confidentiality of an individual’s 
identifiable genetic information is preserved.  More uniformity is necessary in order to create 
less confusion on the type of conduct that is regulated.   
Although the proposed amendments to HIPAA may establish more uniformity it is likely not 
a practicable recommendation.  It would probably take Congress many years to amend a federal 
statute, such as HIPAA.  In order to effectively regulate research laboratories and tissue banks, 
the states will probably have to continue to take the initiative by establishing comprehensive 
informed consent procedures prior to any “genetic test.”  A comprehensive informed consent 
procedure will ensure that an individual’s identifiable genetic information is not disclosed to an 
unauthorized third party, such as employers and/or health insurance providers.  Also, expanding 
the definition of what constitutes a “genetic test” will ensure that certain research laboratories 
and tissue banks are properly regulated.       
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V. Conclusion       
Genetics research is critical to the study and treatment of diseases; however, there is a 
substantial privacy concern with respect to an individual’s identifiable genetic information after 
the research and/or testing has been completed.  Certain research laboratories or other entities not 
covered under federal or state legislation may freely disseminate an individual’s identifiable 
genetic information to third parties, which could result in various types of discrimination by 
employers and/or health insurance providers.  The aforementioned proposals would preserve the 
confidentiality of an individual’s identifiable genetic information while still allowing for the 
scientific advancement of genetics research in order to benefit humanity.     
 
